… emphasize combination bronchodilators as a mainstay of therapy for many patients with
symptomatic COPD and there are several new combination bronchodilator therapies available …

… In all current guidelines and recommendations of the management of COPD, inhaled
bronchodilators are the pillar of therapy at each stage of the disease.1, 2, 3 In particular, results of …

… meta-analysis comparing dual bronchodilator therapy versus … concluded that dual
bronchodilator therapy significantly reduced … for COPD recommended dual bronchodilator …

… a dose of 25 μg (triple therapy), as compared with fluticasone furoate–vilanterol (at doses of
100 μg and 25 μg, respectively) or the dual bronchodilator umeclidinium–vilanterol (at doses …

… bronchodilator therapies. Real world evidence for the benefits of combination therapy … (LAMA)
or long-acting beta2-agonist (LABA) or dual therapy (DT) with a LAMA/LABA fixed dose …

… on a dual bronchodilator therapy are less likely to switch therapy compared to individuals
who initiate on a monotherapy bronchodilator. Participants in the dual therapy cohort reported …

… exacerbators12, 13 may benefit more from dual bronchodilation than LABA/ICS, in contrast
to … escalation to triple therapy in patients initiating LABA/LAMA or LABA/ICS in primary care. …

… Several studies have documented that long-acting bronchodilators can reduce
exacerbation rate and/or severity, and others have shown that combinations of long-acting β 2 -…

… (COPD), inhaled bronchodilator therapy can help to improve … a combination of two
bronchodilators (dual therapy) either with … patients who received triple therapy (dual therapy plus …

Introduction a≥ 1 moderate or severe exacerbation in the previous year. COPD, chronic
obstructive pulmonary disease; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA…